Weight Loss Supplements |
|
|
Clinical Trial: Genetics, Metabolism and Weight Loss in Older, Obese Veterans
This study has been completed.
|
Purpose
This study is designed to determine whether sequence variation in the lipoprotein lipase (LPQ) gene affects the amount of weight loss and metabolic responses during a hypocaloric diet treatment for overweight and obese (BMI=25-35 kg/m2), older (50-65 yrs), sedentary veterans.
| Condition | Treatment or Intervention |
|---|---|
| Obesity | Behavior: Weight Loss |
MedlinePlus related topics: Obesity
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Uncontrolled, Single Group Assignment, Efficacy Study
Study start: April 1999; Study completion: March 2004
Veterans who are 50-65 yrs, non-smoking, sedentary and weight stable with a BMI between 25-35 kg/m2 (120-150% desirable body weight) are recruited and screened via telephone, medical history, and physical exam. Exclusion criteria are: diabetes, hypertriglyceridemia (>400 mg/dl), history of cancer or myocardial infarction, clinical depression, renal, liver or hematologic disease, and medications that affect glucose or lipid metabolism (thiazides, estrogen replacement, beta-blockers). Changes in total and visceral body fat are measured by dual x-ray absorptiometry and computerized tomography, resting energy expenditure and fat oxidation rate by indirect calorimetry, and lipoprotein lipids by enzymatic assay. Glucose tolerance is assessed during a three-hour oral glucose tolerance test with measurement of glucose- and insulin levels every 30 minutes. LPL activity is measured in 3050mg pieces of subcutaneous abdominal and gluteal adipose tissue.
Eligibility
Ages Eligible for Study: 50 Years - 65 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
- 50-65 yrs, non-smoking, sedentary and weight stable with a BMI between 25-35 kg/m2 (120-150% desirable body weight) are recruited and screened via telephone, medical history, and physical exam.
Exclusion criteria:
- Diabetes,
- Hypertriglyceridemia (>400 mg/dl),
- History of cancer or myocardial infarction,
- Clinical depression,
- Renal, liver or hematologic disease, and
- Medications that affect glucose or lipid metabolism (thiazides, estrogen replacement, beta-blockers).
Location Information
Maryland
VA Maryland Health Care System, Baltimore, Maryland, 21201, United States
More Information
Record last reviewed: December 2004
Last Updated: December 30, 2004
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018330
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


